Effect of recombinant human growth hormone in elderly osteoporotic women

Sugimoto, Toshitsugu; Nakaoka, Daiki; Nasu, M; Kanzawa, Michiko; Sugishita, Takeshi; Chihara, Kazuo

doi:10.1046/j.1365-2265.1999.00867.x

Cited by 33 publications

(31 citation statements)

References 64 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, GH treatment in GH-deficient adults increased BMD at the lumbar spine and femoral neck for up to 30 -36 months, with a plateau thereafter (28). Our previous study (14) revealed that, when BMD continued to be monitored after discontinuation of GH treatment for another 48 weeks, significant increases in radial and lumbar BMD (8:1^2:1% and 3:8^1:4% above pretreatment values respectively) were observed in elderly women with osteoporosis. In the previous study, GH was administered at 0.00595 mg/kg per day for the first 4 weeks and subsequently at 0.0119 mg/kg per day for 48 weeks.…”

Section: Discussionmentioning

confidence: 98%

“…To establish the clinical utility of GH in osteoporosis in the elderly, GH treatment must be shown to have significant long-term anabolic effects without deleterious side effects. Some patients receiving GH treatment exhibited minor side effects such as edema and joint pain (14). We therefore used GH 0.00595 mg/kg per day for 48 weeks in the present study, which was half the GH dose used in our previous study (14).…”

Section: Discussionmentioning

confidence: 99%

“…Some patients receiving GH treatment exhibited minor side effects such as edema and joint pain (14). We therefore used GH 0.00595 mg/kg per day for 48 weeks in the present study, which was half the GH dose used in our previous study (14). Our findings that treatment with GH 0.00595 mg/kg per day for 48 weeks did not affect BMD at mid-radius and lumbar spine were similar to those obtained in our previous study with GH 0.0119 mg/kg per day (14).…”

Section: Discussionmentioning

confidence: 99%

“…However, controversy exists as to whether GH treatment would increase BMD in patients with senile osteoporosis (10,11). Our recent study revealed that GH treatment (0.25 IU/kg per week for 48 weeks) attenuated the decreases in muscle strength and bone mass and the gain in abdominal fat seen with aging in elderly Japanese women with osteoporosis (14), raising the possibility that GH would be useful in the treatment of osteoporosis. However, a few patients receiving the GH treatment had side effects such as edema and joint pain.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis

Sugimoto

Kaji²,

Nakaoka³

et al. 2002

European Journal of Endocrinology

View full text Add to dashboard Cite

Background: There has been increasing evidence that the growth hormone (GH) -IGF-I axis plays an important part in the maintenance of bone mass. However, controversy still exists as to the effect of GH treatment on bone mineral density (BMD) in elderly patients with osteoporosis. Objective: To investigate the effect of low-dose GH treatment on markers of body composition and bone turnover, serum concentrations of IGF-I and IGF-binding proteins (IGFBPs), and BMD at the radius and lumbar spine in eight elderly Japanese women with osteoporosis. Methods: Participants were treated with GH as a single daily subcutaneous injection (0.125 IU/kg per week; 0.00595 mg/kg per day) for 48 weeks. Results: Markers of bone formation and bone resorption were both increased up to 24 weeks of GH treatment. The bone formation markers remained increased during GH treatment, whereas the bone resorption markers returned to baseline values after 24 weeks of GH treatment. GH treatment caused a rapid (within 2 weeks) and sustained increase in serum IGF-I concentration. As for IGFBPs, serum concentrations of IGFBPs-2, -3 and -4 did not change significantly during GH treatment. In contrast, GH treatment caused a gradual increase in serum IGFBP-5 concentration, with a significant increase seen 48 weeks after the start of GH treatment. Radial BMD seemed to be increased during the late period of GH treatment, although the change was not significant. Lumbar BMD did not change during GH treatment. GH treatment caused a significant increase in hand grip strength. None of the GH-treated participants had new fractures and side effects such as edema and joint pain. Radial BMD was significantly increased after discontinuation of GH treatment for another 48 weeks and a similar tendency was observed at the lumbar spine (7:1^2:3% above pretreatment values for the radius and 3:6^2:0% for the lumbar spine). Conclusions: Low-dose GH treatment attenuated the decrease in muscle strength and bone mass in elderly women without side effects, although changes in nutrition and exercise might affect BMD. The present findings provide useful information regarding the use of low-dose GH treatment in elderly women with osteoporosis.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis

Sugimoto

Kaji²,

Nakaoka³

et al. 2002

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Growth hormone has been used as a bone anabolic agent in GH-deficient patients [9,[20][21][22][23] and in some situations where the main factor causing osteoporosis was the decrease in osteoblastic function, such as anorexia nervosa [24], age [25] and idiopathic osteoporosis [26,27].…”

Section: Resultsmentioning

confidence: 99%

Additional Beneficial Effects of Recombinant Growth Hormone in Alendronate-treated Patients with Idiopathic Osteoporosis

2009

View full text Add to dashboard Cite

Abstract. In order to study the benefit of adding recombinant human growth hormone (rhGH) to antiresorptive therapy, six patients with idiopathic osteoporosis (IO) receiving alendronate plus calcium and vitamin D were started on daily subcutaneous injections of rhGH 2.0 IU for one year. Fasting morning urine and serum samples were collected for N telopeptide of type-1 collagen (NTX), serum bone-specific alkaline phosphatase (BSAP) and insulin-like growth factor 1 (IGF-1) during the study. Bone mineral density (BMD) was determined by dual-energy x-ray absorptiometry at baseline and 01 year. The effect of rhGH was evaluated comparing the percentage changes in BMD during the last year on ALN with the results obtained with the combined therapy. Serum IGF-1 increased in all patients but variations were not significant (p=0.266). Serum BSAP did not significantly change (p=0.078) but median NTX increased at 45 days from 12.3 to 19.8 nMBCE/mMCr (p=0.012) and tended to return to baseline values at 12 months (15.2 nMBCE/mMCr). Comparing with isolated ALN therapy, a beneficial effect on bone density was observed in 2/3 of the patients at lumbar spine, and percentage change (median and quartiles) varied from -0.65% (-2.33 and 2.23) on ALN to 0.70% (-0.35 and 3.03) on ALN+GH. Although no bone gain occurred at the femoral neck, our data point to a positive effect of rhGH in patients with idiopathic osteoporosis.

show abstract

Insulin-like Growth Factor-I in Muscle Metabolism and Myotherapies

Singleton

Feldman

2001

Neurobiology of Disease

View full text Add to dashboard Cite

Effect of recombinant human growth hormone in elderly osteoporotic women

Abstract: These results indicate that GH attenuates the decrease in muscle strength and bone mass as well as the gain of abdominal fat with ageing in elderly women. The present data provide useful information about the application of GH treatment in elderly women.

Cited by 33 publications

References 64 publications

Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis

Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis

Additional Beneficial Effects of Recombinant Growth Hormone in Alendronate-treated Patients with Idiopathic Osteoporosis

Insulin-like Growth Factor-I in Muscle Metabolism and Myotherapies

Contact Info

Product

Resources

About